top of page
Cluster News
Standardize and scale tumor organoids to accelerate innovation in oncology.
On April 7, 2026, the Ecosystem Breakfast took place on the theme " Standardize and scale tumor organoids to accelerate innovation in oncology"; the replay is now available. With : Benjamin Saulnier: CEO of Cellura (SoftCell Therapeutics) . Access the replay
Apr 7
InnPROGRESS platform: Gustave Roussy's expertise in clinical trial design
On March 10, 2026, the Ecosystem Breakfast was held on the theme “InnPROGRESS platform: Gustave Roussy's expertise in clinical trial design.” The replay is now available. With: Prof. Benjamin Besse: Professor Benjamin Besse is Director of Clinical Research at Gustave Roussy and Professor of Medical Oncology at Paris-Saclay University. As a medical oncologist, his research focuses on the application of personalized therapeutic strategies based on molecular abnormalities, circ
Mar 11
PSCC Innovation Forum 2026 replays are available!
Relive the Innovation Forum 2026! Find the program at this link. Replays of the program: Welcome address Eric Vivier, PSCC: #1: Progress in Oncologic Surgery Olaf Mercier , Marie Lannelongue Hospital, France. Personalized surgery for lung cancer: #2: Pushing Boundaries in Cancer Treatment Norbert Pardi, Pennsylvania University, US Lipid nanoparticles for mRNA vaccine delivery Antonin de Fougerolles, Etherna, US Optimizing mRNA and LNP for better vaccines and therapeutics i
Mar 3
Alternative Species in Regulatory Toxicology: How to Reduce Your Budget While Preserving Scientific Robustness
On February 17, 2026, the Ecosystem Breakfast took place on the theme "Alternative Species in Regulatory Toxicology: How to Reduce Your Budget While Preserving Scientific Robustness " ; the replay is now available. With : Alexandre Bidaut Head of Alliance Management, ERBC Group Trained as a veterinary pathologist, Alexandre has been coordinating regulatory and non-regulatory preclinical studies for over 20 years within pharmaceutical companies and contract research organi
Feb 17
Reinventing liquid biopsy: towards integrative and personalized medicine
On January 27, 2026, the Ecosystem Breakfast took place on the theme "Reinventing liquid biopsy: towards integrative and personalized medicine " ; the replay is now available. With : Aline Cerf, SmartCatch Access the replay
Jan 28
Deeptech in Glioblastoma
On January 22, 2026, the PSCC and Brain&Mind jointly brought together, at The Hive building on Campus Grand Parc (Villejuif), a broad range of stakeholders involved in innovation in glioblastoma — clinicians, researchers, biotech, medtech and pharmaceutical companies, patients and patient representatives, as well as institutional stakeholders. The objective of this event was to take stock of the latest advances in glioblastoma, to discuss future perspectives from technologica
Jan 22
What uses are there for ARCAD databases?
On January 13, 2026, the Ecosystem Breakfast took place on the theme " What uses are there for ARCAD databases?" , the replay is now available With : Ségolène de Retz is Chief Executive Officer of the Fondation ARCAD . Jean-Baptiste Bachet , MD, PhD, is a digestive oncologist specialized in colorectal and pancreatic cancers. He is involved in numerous clinical and translational research studies and is a member of GERCOR (Groupe d'Étude et de Recherche Clinique en
Jan 13
Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients
The Ecosystem Breakfast took place on December 16, 2025, moderated by Céline Capéra , Head of Sales, IntegraGen, and Charles Marcaillou , Head of R&D, IntegraGen. and Séverine Matin-Lannerée , PhD, Head of Quality, IntegraGen The replay of the presentation on the topic " Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients " is now available . Access the replay
Dec 17, 2025
Cluster News
Paris-Saclay Cancer Cluster announces the 10 BOOST Grant laureates
Grants ranging from €120,000 to €250,000 to help 10 high-potential oncology start-ups advance towards critical value-creating milestones • Against a backdrop of tougher funding conditions for innovative companies, the PSCC is strengthening its role as an operational accelerator • The BOOST Grant is designed to fund the critical milestones that determine access to investors, industry partners, the clinic or the market • The laureates’ projects span the full onco
Jun 2
In Villejuif, the Paris-Saclay Cancer Cluster deploys an operational model to accelerate innovation in oncology
Villejuif, February 4, 2026 - On World Cancer Day , the Paris-Saclay Cancer Cluster (PSCC) is hosting the 3rd edition of its PSCC Innovation Forum in Villejuif. More than 700 oncology stakeholders -researchers, clinicians, start-ups, industrial players, investors, and patient representatives - are gathering around a shared conviction: t he future of oncology now lies in the ability to rapidly translate scientific innovation into tangible clinical impact. Each year, nearly 4
Feb 4
(In French) Hack4Hope 2025 : Ensemble pour transformer la prise en charge des cancers pédiatriques
Une deuxième édition ambitieuse dédiée aux cancers de l’enfant et de l’adolescent , organisée par le PSCC et son Childhood Cancer Working Group, avec le soutien de LifeArc, Foundation S, Imagine for Margo, Sanofi et Bristol Myers Squibb. 9 projets finalistes sélectionnés parmi 24 candidatures, couvrant thérapies innovantes, IA, diagnostics, nanomédecine et soutien aux familles. 4 gagnants distingués par le jury : Kindling Bio (1er Prix), MSInsight (2e Prix), Hippoxis (3e Pr
Dec 5, 2025
(In French) À The Hive, le Central Lab et l’Innovation Center dévoilent leur offre aux sociétés innovantes en oncologie du PSCC
Premier événement scientifique organisé au sein de The Hive , bâtiment totem du biocluster, au cœur du Campus Grand Parc Lancement du Central Lab , bientôt opérationnel pour accompagner les projets précliniques et cliniques Déploiement de l’ Innovation Center , une offre modulable destinée aux jeunes start-ups Présentation de deux nouveaux locataires de The Hive : Valerio Therapeutics , et Signadori Bio Villejuif, le 04 décembre 2025 – Organisée à The Hive, bâtiment de 25
Dec 4, 2025
Cluster News
IA4Clinical Trials Symposium
Yesterday, more than 120 participants gathered at The Hive for the AI 4 Clinical Trials Symposium, co-organised by Future4Care and PSCC Connect. The day opened with an inspiring keynote by Stéphanie Allassonnière (Université Paris Cité), "Smarter Trials, Faster Cures: The AI Revolution in Clinical Research." Her presentation highlighted a clear message: AI is no longer a promise—it is already transforming every stage of clinical research. Throughout the morning, three e
2 days ago
Tailored Antigens, Leaner Workflows: Accelerating Therapeutic Antibody and ADC Discovery
On 23 June 2026, the Ecosystem Breakfast took place on the theme “Tailored Antigens, Leaner Workflows: Accelerating Therapeutic Antibody and ADC Discovery.” The presentations are available below. Please note that no replay is available. with: Jacques Fieschi, Chief Scientific Officer, MImAbs Thomas Vinos-Poyo, Account Manager, ACROBiosystems AG
Jun 25
New oncology innovators join the PSCC BOOST programme
This quarter, eight innovative oncology-focused projects have been selected to join the BOOST programme of the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence, and international reach of the ecosystem. From cancer vaccines and oncolytic viruses to precision immunotherapies, ADC technologies, photodynamic therapies, and innovative diagnostics, these projects illustrate the breadth of approaches supported by PSCC to accelerate the
Jun 22
Canceropôle Île-de-France and the PSCC are joining forces to accelerate innovation in oncology in the Île-de-France region
Le canceropôle IDF et le Paris Saclay Cancer Cluster ont officialisé un partenariat destiné à accélérer l'innovation en oncologie sur le territoire francilien.
Jun 12
Cluster News
New oncology innovators join the PSCC BOOST programme
This quarter, eight innovative oncology-focused projects have been selected to join the BOOST programme of the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence, and international reach of the ecosystem. From cancer vaccines and oncolytic viruses to precision immunotherapies, ADC technologies, photodynamic therapies, and innovative diagnostics, these projects illustrate the breadth of approaches supported by PSCC to accelerate the
Jun 22
New start-ups join the PSCC BOOST programme
Five innovative oncology-focused projects have been selected through the BOOST programme and join the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence and ambition of the ecosystem. From cell therapies to gene delivery, theranostics, vaccines and advanced imaging technologies , these projects illustrate the breadth of approaches supported by PSCC to accelerate the translation of scientific breakthroughs into tangible impact for p
Mar 25
New start-ups join the PSCC BOOST programme
For the beginning of 2026, five innovative oncology-focused projects were successful in the selection process and join the BOOST programme of the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence and ambition of the ecosystem. From novel therapeutic modalities to next-generation biologics , these projects illustrate the breadth of approaches supported by PSCC to accelerate the translation of breakthrough science into tangible imp
Jan 7
9 new projects supported by the PSCC
From diagnosis to therapies, from molecules to algorithms: innovation takes multiple forms within the Paris Saclay Cancer Cluster (PSCC)....
Sep 25, 2025
Cluster News
Les Echos - A Villejuif, le cluster de l'oncologie prend de l'ampleur (in french)
Huit entreprises, 250 salariés et un fonds de subvention de 2,5 millions d'euros… Le Paris-Saclay Cancer Cluster met les bouchées doubles à Villejuif pour accélérer le passage de la recherche à la fabrication de traitement contre le cancer. Le Paris-Saclay Cancer Cluster met les bouchées doubles. Ce cluster, financé par l'Etat à hauteur de 100 millions d'euros, développe un pôle consacré à l'oncologie et à la déclinaison de la recherche en traitement pour trouver des solution
Feb 6
Mind Health - Le PSCC dévoile ses ambitions pour 2026 (in French)
Le Paris-Saclay Cancer Cluster (PSCC), le biocluster dédié à l'oncologie, a présenté le 4 février un bilan de son activité depuis sa création en 2022 à l'occasion du PSCC Innovation Forum 2026. Son Campus, doté d'un investissement de 1,8 Mds €, sort progressivement de terre : 45 000 m² de laboratoires et de bureaux sont opérationnels depuis 2025. En janvier, sept entreprises, dont Sanofi et One Biosciences, ont déjà rejoint le cluster et le PSCC vise l'installation de plus de
Feb 6
L'Express - Visite exclusive au cœur du "Paris-Saclay Cancer Cluster" : "Grâce à cet incubateur, tout va plus vite (in french)
Reportage. Sous l’impulsion d’Emmanuel Macron, la France tente d’ériger à Villejuif un incubateur géant pour aider les scientifiques à transformer leurs idées en médicaments. C'est vrai que l'on s’y perd dans ces couloirs où rien n’est indiqué, au milieu de toutes ces salles nues, qui attendent encore qu’on les habille de meubles et de moquettes. Le "Paris-Saclay Cancer Cluster", projet d’incubateur inédit en France, n’est pas tout à fait fini, et cela se devine à tous ces sa
Feb 3
L'Express - Cancer, les vrais progrès de la science : "La frontière de la guérison a bougé"
Sciences et santé. Les médecins arrivent désormais à prolonger la vie de certains patients atteints de tumeurs métastatiques. Une révolution, même si le cancer reste la première cause de décès dans notre pays. On dit de Valérie, 56 ans, qu’elle a "bonne mine". Qu’elle n’a pas l’air "malade". Peut-être est-ce dû à cet infatigable entrain, elle qui a toujours eu une énergie "débordante" et mille projets à la fois, cadre dans l’assurance et élue d’une petite commune du sud de la
Nov 26, 2025
Cluster News
IA4Clinical Trials Symposium
Yesterday, more than 120 participants gathered at The Hive for the AI 4 Clinical Trials Symposium, co-organised by Future4Care and PSCC Connect. The day opened with an inspiring keynote by Stéphanie Allassonnière (Université Paris Cité), "Smarter Trials, Faster Cures: The AI Revolution in Clinical Research." Her presentation highlighted a clear message: AI is no longer a promise—it is already transforming every stage of clinical research. Throughout the morning, three e
2 days ago
Tailored Antigens, Leaner Workflows: Accelerating Therapeutic Antibody and ADC Discovery
On 23 June 2026, the Ecosystem Breakfast took place on the theme “Tailored Antigens, Leaner Workflows: Accelerating Therapeutic Antibody and ADC Discovery.” The presentations are available below. Please note that no replay is available. with: Jacques Fieschi, Chief Scientific Officer, MImAbs Thomas Vinos-Poyo, Account Manager, ACROBiosystems AG
Jun 25
New oncology innovators join the PSCC BOOST programme
This quarter, eight innovative oncology-focused projects have been selected to join the BOOST programme of the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence, and international reach of the ecosystem. From cancer vaccines and oncolytic viruses to precision immunotherapies, ADC technologies, photodynamic therapies, and innovative diagnostics, these projects illustrate the breadth of approaches supported by PSCC to accelerate the
Jun 22
Canceropôle Île-de-France and the PSCC are joining forces to accelerate innovation in oncology in the Île-de-France region
Le canceropôle IDF et le Paris Saclay Cancer Cluster ont officialisé un partenariat destiné à accélérer l'innovation en oncologie sur le territoire francilien.
Jun 12
bottom of page